Verberne A A
Ignatius Ziekenhuis, Breda, The Netherlands.
Pediatr Pulmonol Suppl. 1997 Sep;15:46-50.
International guidelines indicate that the primary goals of asthma treatment are minimizing symptoms and preventing exacerbations. Symptoms last for short periods of time (minutes or hours) and usually disappear either spontaneously or with the use of bronchodilator therapy. Exacerbations last for 1 or more days and need more extensive bronchodilator therapy with the possible addition of a course of oral corticosteroids. Particularly in children, because of their active life style, exercise-induced symptoms may interfere with normal daily life, and nocturnal symptoms may cause severe sleep disturbance. Although the avoidance of triggers that provoke symptoms and exacerbations is advocated in the guidelines, this is not a practical option as it is extremely difficult for asthmatic children to lead a normal life and yet avoid exercise. Long-term use of medication is therefore necessary to achieve the treatment goals. Inhaled corticosteroids have been shown to be the most effective drugs for reducing asthma symptoms and exacerbations. However, most children will not be free of symptoms during corticosteroid therapy and intermittent use of bronchodilator therapy is required. Cessation of inhaled corticosteroid therapy, even after several years of use, is likely to result in a reoccurrence of asthma symptoms. Long-acting beta 2-agonists, such as salmeterol and formoterol, are now available as additional therapy to inhaled corticosteroids in patients who remain symptomatic despite at least a moderate dose of inhaled corticosteroid. Two recent studies in adults revealed addition of salmeterol superior to increasing inhaled corticosteroid dose. So far, no data in children are available, but theoretically it might be attractive to add a long-acting beta 2-agonist to on-going therapy for children who remain symptomatic, especially at nighttime, despite the use of inhaled corticosteroids. There is no place for the use of long-acting beta 2-agonists as monotherapy in pediatric patients.
国际指南指出,哮喘治疗的主要目标是将症状降至最低并预防病情加重。症状持续时间较短(数分钟或数小时),通常会自行消失或通过使用支气管扩张剂治疗而消失。病情加重持续1天或更长时间,需要更广泛的支气管扩张剂治疗,可能还需加用一个疗程的口服糖皮质激素。特别是在儿童中,由于他们活跃的生活方式,运动诱发的症状可能会干扰正常的日常生活,夜间症状可能会导致严重的睡眠障碍。尽管指南提倡避免引发症状和病情加重的触发因素,但这并非实际可行的选择,因为哮喘儿童要过上正常生活且避免运动极为困难。因此,长期使用药物对于实现治疗目标是必要的。吸入性糖皮质激素已被证明是减轻哮喘症状和病情加重最有效的药物。然而,大多数儿童在糖皮质激素治疗期间仍会有症状,需要间歇性使用支气管扩张剂治疗。即使使用数年吸入性糖皮质激素治疗后停药,哮喘症状也可能复发。长效β2受体激动剂,如沙美特罗和福莫特罗,现在可作为吸入性糖皮质激素的附加疗法用于那些即使使用至少中等剂量吸入性糖皮质激素仍有症状的患者。最近两项针对成人的研究表明,加用沙美特罗优于增加吸入性糖皮质激素剂量。到目前为止,尚无儿童方面的数据,但从理论上讲,对于那些即使使用吸入性糖皮质激素仍有症状,尤其是夜间有症状的儿童,在持续治疗中加用长效β2受体激动剂可能具有吸引力。长效β2受体激动剂在儿科患者中不作为单一疗法使用。